2018
<i>Leishmania guyanensis</i> parasites block the activation of the inflammasome by inhibiting maturation of IL-1β
Hartley M, Eren R, Rossi M, Prevel F, Castiglioni P, Isorce N, Desponds C, Lye L, Beverley S, Drexler S, Fasel N. Leishmania guyanensis parasites block the activation of the inflammasome by inhibiting maturation of IL-1β. Microbial Cell 2018, 5: 137. PMID: 29487860, PMCID: PMC5826701, DOI: 10.15698/mic2018.03.619.Peer-Reviewed Original ResearchRIG-like receptorsInflammasome pathwayInnate pattern recognition receptorsPotent innate immunogenPattern recognition receptorsCytoplasmic dsRNA sensorsLesional inflammationTLR3 pathwaySymptomatic outcomeIL-1βInflammatory pathologyInflammatory responseInflammasome activationCutaneous leishmaniasisRecognition receptorsParasite burdenReceptor 3DsRNA sensorsVirus 1InfectionPathologyViral dsRNA genomeInflammasomeA20 proteinLRV1
2016
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F, Couppié P, Hickerson S, Launois P, Beverley S, Ronet C, Fasel N. Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLOS Pathogens 2016, 12: e1005852. PMID: 27658195, PMCID: PMC5033371, DOI: 10.1371/journal.ppat.1005852.Peer-Reviewed Original ResearchIL-17AMurine modelMetastatic leishmaniasisDisease chronicityHuman patientsInflammatory cytokines IL-17AIL-17A inhibitionPotent innate immunogenPresence of LRV1Cytokines IL-17AAbsence of IFNMetastatic complicationsImmunologic mechanismsStandard therapyCytokines IFNPrognostic valueOpen ulcerationDisease outcomeCutaneous leishmaniasisSecondary sitesSignificant associationLeishmania parasitesTherapeutic promiseLeishmaniasisLRV1Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus
Parmentier L, Cusini A, Müller N, Zangger H, Hartley M, Desponds C, Castiglioni P, Dubach P, Ronet C, Beverley S, Fasel N. Severe Cutaneous Leishmaniasis in a Human Immunodeficiency Virus Patient Coinfected with Leishmania braziliensis and Its Endosymbiotic Virus. American Journal Of Tropical Medicine And Hygiene 2016, 94: 840-843. PMID: 26834198, PMCID: PMC4824227, DOI: 10.4269/ajtmh.15-0803.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLeishmania infectionCutaneous leishmaniasisPresence of LRV1Primary skin lesionsDrug treatment failureAggressive pathogenesisAntiretroviral therapyHIV patientsSpecies of LeishmaniaMurine leishmaniasisTreatment failureImmunodeficiency virusNasal lesionsRisk factorsEmergence of leishmaniasisSkin lesionsCutaneous afflictionsFurther exacerbationDisease severityLeishmania parasitesLeishmaniasisLeishmania braziliensisLRV1Patients
2015
Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse
Bourreau E, Ginouves M, Prévot G, Hartley M, Gangneux J, Robert-Gangneux F, Dufour J, Sainte-Marie D, Bertolotti A, Pratlong F, Martin R, Schütz F, Couppié P, Fasel N, Ronet C. Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse. The Journal Of Infectious Diseases 2015, 213: 105-111. PMID: 26123564, DOI: 10.1093/infdis/jiv355.Peer-Reviewed Original ResearchConceptsL. guyanensis infectionLeishmania RNA virus 1American tegumentary leishmaniasisSymptomatic relapseTreatment failureTegumentary leishmaniasisFirst-line treatment failureDoses of pentamidineLeishmania guyanensis infectionLine treatment failureFirst-line treatmentChronic cutaneous leishmaniasisVirus 1Second-line drugsExperimental murine leishmaniasisInflammatory markersHyperinflammatory responseExtended therapyMurine leishmaniasisTherapeutic choiceSuch complicationsRNA virus 1Persistent infectionCutaneous leishmaniasisRelapse
2013
The therapeutic potential of immune cross‐talk in leishmaniasis
Hartley M, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross‐talk in leishmaniasis. Clinical Microbiology And Infection 2013, 19: 119-130. PMID: 23398405, DOI: 10.1111/1469-0691.12095.Peer-Reviewed Original ResearchConceptsMetastatic leishmaniasisCutaneous leishmaniasisLeishmania parasitesSelf-healing lesionsProtozoan parasitic diseaseEffective antileishmanial drugsSpecies of LeishmaniaDestructive lesionsImmune homeostasisCurrent treatmentTherapeutic strategiesImmune pathwaysNew drug targetsTherapeutic potentialParasitic diseasesAntileishmanial drugsLeishmaniasisLesionsPrevalent formDiseaseDrug targetsRNA virusesTreatmentVariable effectsParasitesDetection of Leishmania RNA Virus in Leishmania Parasites
Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J, Hartley MA, Prevel F, Castiglioni P, Pratlong F, Bastien P, Müller N, Parmentier L, Saravia NG, Beverley SM, Fasel N. Detection of Leishmania RNA Virus in Leishmania Parasites. PLOS Neglected Tropical Diseases 2013, 7: e2006. PMID: 23326619, PMCID: PMC3542153, DOI: 10.1371/journal.pntd.0002006.Peer-Reviewed Original ResearchConceptsLeishmania RNA virusCutaneous leishmaniasisSkin lesionsPresence of LRVHyper-inflammatory immune responsePrimary skin lesionsUlcerated skin lesionsOverall exacerbationsSignificant morbidityInfected miceLesion biopsyRNA virusesSecondary lesionsImmune responseHigh riskNew World Leishmania speciesAggressive phenotypeLeishmania strainsLeishmania parasitesPatient samplesViral detectionMonoclonal antibodiesNasopharyngeal tissuesParasite strainsMetastatic phenotype